Kyverna Therapeutics, Inc

Founded in 2006, Zogenix Inc. is a privately held, specialty pharmaceutical company. It develops and commercializes differentiated central nervous system (CNS) and pain therapeutics that can address significant unmet medical needs or overcome limitations of existing products. Zogenix Inc has received approval from the Food and Drug Administration (FDA) for SUMAVEL DosePro (sumatriptan injection) needle-free delivery system, which is a drug-device combination that enables needle-free delivery of subcutaneous sumatriptan for the treatment of acute migraine and cluster headache. The company s other product, ZX002, is a novel controlled release formulation of hydrocodone for the treatment of chronic pain. Zogenix Inc. is supported by several investors, including Abingworth Management Ltd., Clarus Ventures, Domain Associates, Scale Venture Partners, Thomas, McNerney & Partner and others.

Santen is a wholly owned subsidiary of Santen Pharmaceutical. Located in Northern California s Napa Valley, the United States office is comprised of health care professionals with its senior management team totaling more than 20 years of industry experience, knowledge and expertise based exclusively in the ophthalmic field. In early 2004, Santen entered into a partnership agreement with VISTAKON Pharmaceuticals, granting VISTAKON the exclusive U.S. distribution rights to the Santen ophthalmic products QUIXIN 0.5%, BETIMOL 0.25% and 0.5%, and ALAMAST 0.1%, as well as its newest product IQUIX 1.5%, which gained FDA approval in March 2004. Santen is also actively pursuing technological alliances with a number of pharmaceutical companies and research institutes and has investments in an intraocular lens company. Santen opened its doors in the San Francisco Bay Area in 1993.

Napo Pharmaceuticals, Inc. is a San Francisco-based company dedicated to developing and commercializing prescription medicines that provide essential supportive care for individuals undergoing treatment for diseases like cancer. Their mission is to improve the comfort, quality of life, and dignity of patients experiencing treatment-related gastrointestinal distress, particularly overactive bowel symptoms such as chronic diarrhea, urgency, and incontinence. Napo Pharmaceuticals is currently focused on their Phase 3 pivotal OnTarget trial of Mytesi crofelemer, a preventative treatment for chemotherapy-induced overactive bowel, with comprehensive results expected in Q1 2024. They also support investigator-initiated studies exploring the potential of crofelemer for rare disease indications like short bowel syndrome and microvillus inclusion disease. Napo Pharmaceuticals takes pride in their responsible harvesting practices, sourcing their medicines from plants in rainforest regions. Their prescription medicines work through a novel mechanism of action, inhibitory modulation of two secretory chloride ion channels in the gastrointestinal tract. The company is committed to uncovering medical solutions to serve those in need, advancing their understanding through high-quality research conducted by external investigators. Environmental sustainability and social responsibility are paramount to Napo Pharmaceuticals, as they prioritize the responsible harvesting of their products and share benefits with the local communities that contribute to their mission.Generated from the website